For those who have had LAMN PMP please.... I've just been told by Basingstoke that their watch and wait surveillance...

Understanding LAMN with PMP and Surveillance Approaches

Thank you for sharing this important question about your surveillance schedule. This is a significant decision, and I can understand why you'd want to understand the reasoning and hear from others with similar experiences.

What LAMN with PMP Means (Educational Context)

Let me briefly clarify the pathology you're dealing with:

• LAMN = Low-Grade Appendiceal Mucinous Neoplasm (a slow-growing tumor of the appendix)
• PMP = Pseudomyxoma Peritonei (mucin-producing cells in the abdominal cavity)

When LAMN is associated with PMP, it represents a specific clinical scenario that oncologists approach carefully because of the potential for slow progression over many years.

How Doctors Think About Surveillance for LAMN-PMP

The clinical reasoning typically involves:

1. Risk stratification: LAMN-associated PMP is generally considered lower-risk than high-grade appendiceal cancers, but the presence of peritoneal disease means monitoring for progression is important
2. Natural history: These tumors often grow slowly, which influences how frequently imaging is needed
3. Evidence evolution: Surveillance guidelines do change as centers accumulate more long-term outcome data and refine their protocols

The shift from 6-monthly to annual imaging in the first 5 years that Basingstoke describes suggests they've reviewed their patient outcomes and determined that annual intervals still provide adequate detection of clinically significant changes.

Important Questions to Ask Your Team

Since you're navigating this change, these questions could help you understand the reasoning:

1. "What specific outcomes data led to changing from 6-monthly to annual surveillance in the first 5 years?" (This helps you understand if it's based on their institutional experience with LAMN-PMP patients)

2. "Are there any clinical features of MY case that would warrant more frequent imaging than the standard annual schedule?" (This personalizes the recommendation to your specific situation)

3. "What symptoms or changes should I report between scans, and how quickly should I contact you if they occur?" (This ensures you know what warrants urgent evaluation)

4. "How will you use tumor markers alongside imaging, and what changes in markers would prompt more frequent imaging?" (This clarifies the complete monitoring strategy)

5. "What is the evidence base for the 7, 10, 15, and 20-year imaging intervals after year 5?" (This helps you understand the long-term surveillance rationale)

Why This Matters for Your Decision-Making

The shift from 6-monthly to annual imaging represents a more conservative surveillance approach, which typically reflects:

• Confidence in detecting meaningful changes at annual intervals
• Recognition that LAMN-PMP often progresses slowly
• Balancing detection with reducing unnecessary imaging exposure

However, your comfort level with this schedule matters. Some patients prefer more frequent imaging for peace of mind, while others appreciate less frequent scans. This is a legitimate discussion to have with your team.

A Note on Shared Decision-Making

According to guidance on cancer patient engagement, you have the right to understand the reasoning behind surveillance recommendations and to discuss any concerns. If you're uncomfortable with annual imaging, discuss this openly—your team may be able to explain the rationale in more detail or discuss alternatives if there are specific risk factors in your case.

---

Important limitation: I don't have access to specific NCCN or ASCO guidelines that are appendix cancer-specific in my current sources, so I cannot cite the exact evidence base for these surveillance intervals. I'd recommend asking your Basingstoke team for the specific guideline or institutional data they're using, as this will give you the most authoritative information for your situation.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.